In addition to breast and ovarian cancer, patients with medulloblastoma and glioma can carry germline BRCA1/2 deficiency, making these tumors potentially vulnerable to therapy with PARP inhibitors (47, 48). This evidence concerns the gene PARP1 and medulloblastoma.